FI956112A0 - Monoklonaalinen anti- V-integriinivasta-aine - Google Patents

Monoklonaalinen anti- V-integriinivasta-aine

Info

Publication number
FI956112A0
FI956112A0 FI956112A FI956112A FI956112A0 FI 956112 A0 FI956112 A0 FI 956112A0 FI 956112 A FI956112 A FI 956112A FI 956112 A FI956112 A FI 956112A FI 956112 A0 FI956112 A0 FI 956112A0
Authority
FI
Finland
Prior art keywords
monoclonal anti
integrin antibody
integrin
antibody
monoclonal
Prior art date
Application number
FI956112A
Other languages
English (en)
Swedish (sv)
Other versions
FI118536B (fi
FI956112A (fi
Inventor
Francesc Mitjans
Jaume Piulats
Elisabet Rosell
Jaume Adan
Simon Goodman
Diane Hahu
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8216547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI956112(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of FI956112A0 publication Critical patent/FI956112A0/fi
Publication of FI956112A publication Critical patent/FI956112A/fi
Application granted granted Critical
Publication of FI118536B publication Critical patent/FI118536B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
FI956112A 1994-12-20 1995-12-19 Monoklonaalinen anti-alfaV-integriinivasta-aine FI118536B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94120165 1994-12-20
EP94120165 1994-12-20

Publications (3)

Publication Number Publication Date
FI956112A0 true FI956112A0 (fi) 1995-12-19
FI956112A FI956112A (fi) 1996-06-21
FI118536B FI118536B (fi) 2007-12-14

Family

ID=8216547

Family Applications (1)

Application Number Title Priority Date Filing Date
FI956112A FI118536B (fi) 1994-12-20 1995-12-19 Monoklonaalinen anti-alfaV-integriinivasta-aine

Country Status (26)

Country Link
US (1) US5985278A (fi)
EP (1) EP0719859B1 (fi)
JP (1) JP3898245B2 (fi)
KR (1) KR100450368B1 (fi)
CN (1) CN1117763C (fi)
AR (1) AR001778A1 (fi)
AT (1) ATE244306T1 (fi)
AU (1) AU710234B2 (fi)
BR (1) BR9505980B1 (fi)
CA (1) CA2165573C (fi)
CO (1) CO4480042A1 (fi)
CZ (1) CZ290477B6 (fi)
DE (1) DE69531187T2 (fi)
DK (1) DK0719859T3 (fi)
ES (1) ES2202336T3 (fi)
FI (1) FI118536B (fi)
HU (1) HU221061B1 (fi)
NO (1) NO321186B1 (fi)
PL (1) PL182961B1 (fi)
PT (1) PT719859E (fi)
RU (1) RU2205223C2 (fi)
SI (1) SI0719859T1 (fi)
SK (1) SK284932B6 (fi)
TR (1) TR199501614A2 (fi)
UA (1) UA40621C2 (fi)
ZA (1) ZA9510806B (fi)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998009651A1 (fr) * 1996-09-03 1998-03-12 Chugai Seiyaku Kabushiki Kaisha COMPLEXES D'ANTICORPS ANTI-INTEGRINE α3
DE69739295D1 (de) * 1996-12-09 2009-04-23 Merck Patent Gmbh Löslicher, rekombinanter alphaV beta3 Adhäsionsrezeptor
DE69828614T2 (de) * 1997-08-08 2006-02-09 The Regents Of The University Of California, Oakland Behandlung von Nierenfibrose durch Antikörper gegen integrin alpha-v-beta 6
ATE322508T1 (de) * 1998-01-23 2006-04-15 Merck Patent Gmbh Verwendung des antikörpers 271.14d9.f8 (dsm acc2331) um die bindung zwischen alphavbeta6- integrin und fibronectin in vitro zu hemmen
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
US7153944B2 (en) * 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7064180B2 (en) 2000-07-31 2006-06-20 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7323552B2 (en) * 2000-07-31 2008-01-29 The General Hospital Corporation Variant integrin polypeptides and uses thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
CA2439852A1 (en) * 2001-03-02 2002-09-12 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
KR100861466B1 (ko) 2001-04-24 2008-10-02 메르크 파텐트 게엠베하 항혈관형성제 및 ＴＮＦα를 이용한 병용 요법
CA2453403C (en) 2001-07-09 2013-10-08 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity
US7829087B2 (en) * 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
AU2003217930A1 (en) * 2002-03-04 2003-09-22 Medimmune, Llc The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
EP1487489A4 (en) * 2002-03-04 2008-10-01 Medimmune Inc METHODS FOR PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN AVB3 ANTAGONIST ASSOCIATED WITH HMG-COA REDUCTASE INHIBITOR OR BISPHOSPHONATE
WO2003100033A2 (en) 2002-03-13 2003-12-04 Biogen Idec Ma Inc. ANTI-αvβ6 ANTIBODIES
UA90242C2 (ru) * 2002-03-13 2010-04-26 Байоджен Айдек Ма Инк. МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С αVβ6
WO2003087340A2 (en) * 2002-04-12 2003-10-23 Raven Biotechnologies, Inc. Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
WO2003086458A1 (en) 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
JP2006516635A (ja) * 2003-01-30 2006-07-06 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストの使用
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
WO2008060645A2 (en) * 2006-03-21 2008-05-22 Genentech, Inc. Combinatorial therapy involving alpha5beta1 antagonists
BRPI0714381A2 (pt) 2006-07-10 2013-03-05 Biogen Idec Inc composiÇÕes e mÉtodos para inibir crescimento de cÂnceres deficientes em smad4
CA2657581A1 (en) 2006-07-11 2008-01-17 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
JP2010500360A (ja) 2006-08-10 2010-01-07 アルボア コーポレーション 炎症性サイトカイン阻害剤による下気道炎症疾患の局所療法
WO2008141274A1 (en) * 2007-05-11 2008-11-20 Centocor, Inc. Anti-alpha v immunoliposome composition, methods and uses
US20090196913A1 (en) * 2007-05-11 2009-08-06 Ken Shi Kun Huang Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
SI2167128T1 (sl) * 2007-07-17 2013-01-31 Merck Patent Gmbh Z genetskim inĺ˝enirstvom pridobljena hibridna protitelesa proti alfa v- integrinu
AR066170A1 (es) * 2007-09-26 2009-07-29 Genentech Inc Anti integrina alfa 5 beta 1
JP5680547B2 (ja) 2008-12-23 2015-03-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 抗血管形成活性を有するインヒビターのためのバイオマーカー
WO2010111254A1 (en) 2009-03-25 2010-09-30 Genentech, Inc. Novel anti-alpha5beta1 antibodies and uses thereof
EP2498821A1 (en) 2009-11-13 2012-09-19 Merck Patent GmbH Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
AU2011217848B8 (en) * 2010-02-18 2015-09-24 The Regents Of The University Of California Integrin aVB8 neutralizing antibody
WO2012027745A1 (en) * 2010-08-27 2012-03-01 University Of Miami Treatment of renal diseases
KR101972533B1 (ko) 2011-02-11 2019-08-26 메르크 파텐트 게엠베하 전립선암 치료용 항-알파-ｖ 인테그린 항체
CN103826661B (zh) 2011-04-21 2019-03-05 西雅图基因公司 新的结合剂-药物缀合物(adc)及其用途
AU2012296362B2 (en) * 2011-08-17 2017-06-29 The Regents Of The University Of California Antibodies that bind integrin alpha-v beta-8
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
BR112016014830A2 (pt) 2013-12-23 2017-09-19 Bayer Pharma AG Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp
US10435472B2 (en) 2014-09-17 2019-10-08 Merck Patent Gmbh Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
CN107073111A (zh) 2014-09-17 2017-08-18 默克专利股份公司 治疗实体癌和/或其转移的方法、其药物以及预测治疗实体癌和/或其转移的临床结果的方法
CN114917361A (zh) 2015-06-22 2022-08-19 拜耳医药股份有限公司 具有酶可裂解基团的抗体药物缀合物（adc）和抗体前药缀合物（apdc）
MX2017017138A (es) 2015-06-23 2018-04-30 Bayer Pharma AG Conjugados homogeneos especificos de sitio con inhibidores de ksp.
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
JP7034914B2 (ja) 2015-11-23 2022-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維症および／または線維性疾患の治療のための抗α－ｖインテグリン抗体
BR112018069483A2 (pt) 2016-03-24 2019-07-30 Bayer Pharma AG pró-fármacos de medicamentos citotóxicos contendo grupos enzimaticamente cliváveis.
EP3919518A1 (en) 2016-06-15 2021-12-08 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
WO2018046610A1 (en) 2016-09-08 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating nephrotic syndrome
EP3558386A1 (de) 2016-12-21 2019-10-30 Bayer Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
EP3558387B1 (de) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
EP3558388A1 (de) 2016-12-21 2019-10-30 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen
KR101961715B1 (ko) 2018-07-18 2019-03-25 (주) 삼진정밀 고효율 수처리장치
US20200121788A1 (en) 2018-10-19 2020-04-23 Merck Patent Gmbh Abituzumab for the treatment of colorectal cancer
KR101999620B1 (ko) 2019-03-26 2019-07-12 조용진 부상슬러지 및 침전슬러지의 동시처리장치
WO2020210358A1 (en) * 2019-04-08 2020-10-15 Biogen Ma Inc. Anti-integrin antibodies and uses thereof
CN117143241B (zh) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3353209B2 (ja) * 1992-04-03 2002-12-03 ジェネンテク，インコーポレイテッド αｖβ３インテグリンに対する抗体
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis

Also Published As

Publication number Publication date
RU2205223C2 (ru) 2003-05-27
SI0719859T1 (en) 2003-12-31
BR9505980B1 (pt) 2010-02-23
ES2202336T3 (es) 2004-04-01
SK284932B6 (sk) 2006-02-02
JP3898245B2 (ja) 2007-03-28
FI118536B (fi) 2007-12-14
CZ290477B6 (cs) 2002-07-17
NO955167D0 (no) 1995-12-19
UA40621C2 (uk) 2001-08-15
EP0719859A1 (en) 1996-07-03
HUT74828A (en) 1997-02-28
KR100450368B1 (ko) 2005-01-31
KR960022562A (ko) 1996-07-18
TR199501614A2 (tr) 1996-07-21
CA2165573C (en) 2011-03-29
FI956112A (fi) 1996-06-21
HU9503638D0 (en) 1996-02-28
ATE244306T1 (de) 2003-07-15
PT719859E (pt) 2003-11-28
JPH08231597A (ja) 1996-09-10
CZ328895A3 (en) 1996-09-11
DK0719859T3 (da) 2003-10-20
SK159295A3 (en) 1996-07-03
NO955167L (no) 1996-06-21
BR9505980A (pt) 1997-12-23
CO4480042A1 (es) 1997-07-09
CA2165573A1 (en) 1996-06-21
AU4042195A (en) 1996-06-27
HU221061B1 (hu) 2002-07-29
CN1117763C (zh) 2003-08-13
AU710234B2 (en) 1999-09-16
EP0719859B1 (en) 2003-07-02
PL182961B1 (pl) 2002-05-31
ZA9510806B (en) 1996-05-30
AR001778A1 (es) 1997-12-10
PL311926A1 (en) 1996-06-24
DE69531187D1 (de) 2003-08-07
US5985278A (en) 1999-11-16
NO321186B1 (no) 2006-04-03
DE69531187T2 (de) 2004-04-22
CN1139115A (zh) 1997-01-01

Similar Documents

Publication Publication Date Title
FI956112A0 (fi) Monoklonaalinen anti- V-integriinivasta-aine
DK1516629T3 (da) Humaniseret anti-CD-11a antibodies
DE69920897D1 (de) Monoklonale antikörper mit verringerter immunisierungsfähigkeit
DE69617896D1 (de) Humaner monoklonaler Antikörper gegen VEGF
DK145493D0 (da) Antistof
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
DE69738312D1 (de) Hepatitis b monoklonale antikörper
TR199800517A3 (tr) Hümanize anti-hümen fas antikor.
BR9509902A (pt) Fragmentos de anticorpos monoclonais apresentando atividade imunosupressante
DE606516T1 (de) Gegen menschlichen Ceruloplasmin monoklonaler Antikörper.
DE69427850D1 (de) Monoklonaler antikörper gegen mucoglykoprotein
NO985281D0 (no) Monoklonalt antihumant MP52-antistoff
DE69324928T2 (de) Monoklonaler antikörper
BR1100555B1 (pt) anticorpos monoclonais humanizados.
NO20000079D0 (no) Ancrod spesifikke monoklonale antistoff, antistoff- fragmenter, blandinger, derivater og anvendelse derav
FI963901A (fi) Tie-reseptoria tunnistavat monoklonaaliset vasta-aineet ja niiden käyttö
DK0919617T3 (da) Monoklonale antistoffer mod humant MP52
BR1101125A (pt) Imunoglobulina humanizada e composição farmacêutica
DE69320192D1 (de) Monoklonaler antikörper gegen den extravillösen trophoblast

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118536

Country of ref document: FI

MM Patent lapsed